Cytokinetics (CYTK) Cash from Financing Activities (2010 - 2026)

Cytokinetics (CYTK) has reported Cash from Financing Activities for 17 consecutive years, with $7.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 63.44% year-over-year to $7.8 million; the TTM figure through Mar 2026 stood at $527.5 million (down 36.57% YoY), while the FY2025 annual figure was $524.5 million, down 43.64% from the prior year.
• Cash from Financing Activities slipped to $7.8 million in Q1 2026 per CYTK's latest filing, from $110.7 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $821.0 million in Q2 2024 and bottomed at -$7.2 million in Q1 2023.
• Historically, Cash from Financing Activities has averaged $129.4 million across 5 years, with a median of $54.2 million in 2023.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities tumbled 107.65% — and 2024, when it soared 14895.63%.
• Cytokinetics' Cash from Financing Activities stood at $29.9 million in 2022, then jumped by 464.83% to $168.8 million in 2023, then slumped by 98.59% to $2.4 million in 2024, then jumped by 4543.67% to $110.7 million in 2025, then plunged by 92.98% to $7.8 million in 2026.
• Business Quant data shows CYTK's Cash from Financing Activities at $7.8 million in Q1 2026, $110.7 million in Q4 2025, and $330.5 million in Q3 2025.